Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year?
As if Biogen’s aducanumab isn’t controversial enough, the researchers at drug pricing watchdog ICER have drawn up the contours of a new debate: If the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
